Dental Informatics Division, Department of Cariology, Operative Dentistry and Dental Public Health, Indiana University School of Dentistry, IUPUI Indianapolis, IN, USA.
Research Scientist, Center for Biomedical Informatics, Regenstrief Institute, Indianapolis, IN, USA.
Technol Health Care. 2021;29(6):1099-1108. doi: 10.3233/THC-202171.
Limited studies have investigated the medication profile of young adult dental patients despite the high prevalence of prescription opioid abuse in this population.
This study investigated the extent and differences in medication usage of dental patients older than 18 years by age, race/ethnicity, gender, insurance status and mechanism of action in an academic dental clinic setting.
Using an automated approach, medication names in the electronic dental record were retrieved and classified according to the National Drug Code directory. Descriptive statistics, multivariable ANOVA and Post hoc tests were performed to detect differences in the number of medications by patient demographics.
Of the 11,220 adult patients, 53 percent reported taking at least one medication with significant differences in medication usage by demographics. Hydroxymethylglutaryl-coenzyme A reductase inhibitors (21-36%), and angiotensin-converting enzyme inhibitors (19-23%) ranked the top two medication classes among patients 55 years and older. Opioid agonists (7-14%), and Selective Serotonin Reuptake Inhibitors (SSRIs) (5-12%) ranked the top two medication classes among patients aged 18-54 years.
The results underscore the importance of dental providers to review medical and medication histories of patients regardless of their age to avoid adverse events and to determine patient's risk for opioid abuse.
尽管在该人群中阿片类药物滥用的发病率很高,但很少有研究调查年轻成年牙科患者的用药情况。
本研究旨在调查在学术牙科诊所环境中,年龄、种族/民族、性别、保险状况和作用机制不同的 18 岁以上牙科患者的用药程度和差异。
使用自动化方法,从电子牙科记录中检索药物名称,并根据国家药物代码目录进行分类。采用描述性统计、多变量方差分析和事后检验,以检测患者人口统计学特征与用药数量的差异。
在 11220 名成年患者中,53%的患者报告至少使用了一种药物,不同人群的用药情况存在显著差异。羟甲基戊二酰辅酶 A 还原酶抑制剂(21-36%)和血管紧张素转换酶抑制剂(19-23%)在 55 岁及以上患者中排名前两位。阿片类激动剂(7-14%)和选择性 5-羟色胺再摄取抑制剂(SSRIs)(5-12%)在 18-54 岁患者中排名前两位。
研究结果强调了牙科医生无论患者年龄大小,都应审查其医疗和用药史,以避免不良事件,并确定患者阿片类药物滥用的风险。